Фармакоэкономика: открытый доступ

Pharmacoeconomic Analysis of Drug-drug Interactions: Implications for Clinical Practice and Healthcare Costs

Abstract

Rowan Ashwood

Pharmacoeconomic analysis serves as a valuable tool in assessing the economic impact of Drug-Drug Interactions (DDIs) within healthcare systems. DDIs occur when two or more drugs interact with each other, potentially altering their efficacy, safety, or pharmacokinetic properties. These interactions can lead to adverse drug reactions, treatment failure, and increased healthcare costs. Pharmacoeconomic analysis provides a systematic framework for evaluating the costs and outcomes associated with managing DDIs, helping policymakers and healthcare providers make informed decisions about resource allocation, intervention strategies, and patient care. One approach to pharmacoeconomic analysis of DDIs is Cost-Effectiveness Analysis (CEA), which compares the costs and health outcomes of different intervention strategies for preventing or managing drug interactions. This may include measures such as the cost per adverse event avoided, the cost per hospitalization prevented, or the cost per Quality-Adjusted Life-Year (QALY) gained. By quantifying the economic value of interventions in relation to their clinical benefits, CEA provides insights into the cost-effectiveness of various strategies for mitigating the clinical and economic burden of DDIs.